The last one, Beyfortus (nirsevimab-alip), produced in CHOcells, represents a major breakthrough in the fight against RSV (respiratory Syncytial Virus) and is approved for the prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
👉 See fda press-release on July 17:
medicine at all levels: diagnostics, preventionand therapies
We, at Magellan Biologics & Consulting, proudly support R&D in this field at discovery stage by offering solutions for the fast and efficient production of proteins in CHO cells.
🤓 Discover CHO4Tx® , our integrated system for Transient Gene Expression and our 2 options: either we run it for you or we transfer the technology and materials for you to run it in your lab.